Recent progress of supramolecular chemotherapy based on host–guest interactions

M Yan, S Wu, Y Wang, M Liang, M Wang… - Advanced …, 2024 - Wiley Online Library
Chemotherapy is widely recognized as an effective approach for treating cancer due to its
ability to eliminate cancer cells using chemotherapeutic drugs. However, traditional …

The evolving role of radiotherapy in non-small cell lung cancer

S Brown, K Banfill, MC Aznar… - The British journal of …, 2019 - academic.oup.com
Lung cancer is the most commonly diagnosed cancer and biggest cause of cancer mortality
worldwide with non-small cell lung cancer (NSCLC) accounting for most cases …

Macrophage xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer

B Tang, Y Wang, W Xu, J Zhu, Q Weng, W Chen… - Cancer Letters, 2023 - Elsevier
Tumor-associated macrophages (TAMs) play an important role in remodeling the tumor
microenvironment (TME), which promotes tumor growth, immunosuppression and …

[HTML][HTML] A review on curability of cancers: more efforts for novel therapeutic options are needed

S Wang, Y Liu, Y Feng, J Zhang, J Swinnen, Y Li, Y Ni - Cancers, 2019 - mdpi.com
Cancer remains a major cause of death globally. Given its relapsing and fatal features,
curing cancer seems to be something hardly possible for the majority of patients. In view of …

[HTML][HTML] A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation—part 4: systematic review of …

HS Park, FC Detterbeck, DC Madoff… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background Clinical decision-making for patients with stage I lung cancer is complex. It
involves multiple options [lobectomy, segmentectomy, wedge, stereotactic body …

SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung …

KN Franks, L McParland, J Webster… - European …, 2020 - Eur Respiratory Soc
Objectives Stereotactic ablative radiotherapy (SABR) is a well-established treatment for
medically inoperable peripheral stage I nonsmall cell lung cancer (NSCLC). Previous …

Primary tumors of the lung: should we consider thermal ablation as a valid therapeutic option?

J Palussière, V Catena, P Lagarde… - International Journal …, 2019 - Taylor & Francis
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death;
percutaneous thermal ablation (TA) has proven feasibility, good local control and good …

[HTML][HTML] Heart dose and cardiac comorbidities influence death with a cardiac cause following hypofractionated radiotherapy for lung cancer

K Banfill, A Abravan, M van Herk, F Sun… - Frontiers in …, 2022 - frontiersin.org
Background There is increasing evidence of cardiac toxicity of thoracic radiotherapy
however, it is difficult to draw conclusions on cardiac dose constraints due to the …

Unravelling the role of tumor microenvironment responsive nanobiomaterials in spatiotemporal controlled drug delivery for lung cancer therapy

DA Srinivasarao, S Shah, P Famta… - Drug Delivery and …, 2024 - Springer
Abstract Design and development of efficient drug delivery technologies that impart site-
specificity is the need of the hour for the effective treatment of lung cancer. The emergence …

Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's …

A Saha, M Beasley, N Hatton, P Dickinson… - Acta …, 2021 - Taylor & Francis
Purpose/objectives A recent study has shown that tight conformity of lung Stereotactic
Ablative Radiotherapy (SABR) plans might worsen loco-regional control and can predict …